{"id":47928,"date":"2026-05-06T08:46:06","date_gmt":"2026-05-06T06:46:06","guid":{"rendered":"https:\/\/semaxpolska.com\/?p=47928"},"modified":"2026-05-12T08:59:09","modified_gmt":"2026-05-12T06:59:09","slug":"jak-funguje-tesamorelin","status":"publish","type":"post","link":"https:\/\/bioevidencehub.com\/cs\/jak-dziala-tesamorelin\/","title":{"rendered":"Tesamorelin je l\u00e9k pou\u017e\u00edvan\u00fd k l\u00e9\u010db\u011b lipodystrofie, jedn\u00e9 z forem nadm\u011brn\u00e9ho hromad\u011bn\u00ed tuku v t\u011ble. P\u016fsob\u00ed jako syntetick\u00fd analog lidsk\u00e9ho hormonu uvol\u0148uj\u00edc\u00edho r\u016fstov\u00fd hormon (GHRH). GHRH stimuluje hypof\u00fdzu k uvol\u0148ov\u00e1n\u00ed r\u016fstov\u00e9ho hormonu. Tesamorelin napodobuje \u00fa\u010dinek GHRH a t\u00edm zvy\u0161uje hladinu r\u016fstov\u00e9ho hormonu v t\u011ble. Zv\u00fd\u0161en\u00e1 hladina r\u016fstov\u00e9ho hormonu m\u016f\u017ee pomoci sn\u00ed\u017eit mno\u017estv\u00ed viscer\u00e1ln\u00edho tuku (tuku v oblasti b\u0159icha spojen\u00e9ho s rizikem onemocn\u011bn\u00ed srdce a diabetes mellitus 2. typu)."},"content":{"rendered":"<p data-start=\"40\" data-end=\"755\">Tesamorelin je syntetick\u00fd peptid, kter\u00fd pom\u00e1h\u00e1 t\u011blu p\u0159irozen\u011b zvy\u0161ovat produkci a uvol\u0148ov\u00e1n\u00ed r\u016fstov\u00e9ho hormonu (GH). Byl navr\u017een tak, aby napodoboval \u00fa\u010dinek r\u016fstov\u00e9ho hormonu uvol\u0148uj\u00edc\u00edho hormon (GHRH), co\u017e je p\u0159irozen\u00fd hormon produkovan\u00fd v mozku, kter\u00fd vys\u00edl\u00e1 sign\u00e1l hypof\u00fdze k uvoln\u011bn\u00ed GH. Tesamorelin je nejl\u00e9pe zn\u00e1m\u00fd pro sv\u016fj \u00fa\u010dinek na sn\u00ed\u017een\u00ed viscer\u00e1ln\u00edho tukov\u00e9ho tk\u00e1n\u011b (VAT), co\u017e je hlubok\u00fd b\u0159i\u0161n\u00ed tuk hromad\u00edc\u00ed se kolem vnit\u0159n\u00edch org\u00e1n\u016f. Tento typ tuku je siln\u011b spojen s metabolick\u00fdmi probl\u00e9my a lipodystrofi\u00ed spojenou s HIV, co\u017e je porucha distribuce tukov\u00e9 tk\u00e1n\u011b, ke kter\u00e9 doch\u00e1z\u00ed b\u011bhem antiretrovirov\u00e9 terapie.<\/p>\n<p data-start=\"757\" data-end=\"1279\">Tesamorelin p\u016fsob\u00ed vazbou na receptory GHRH v hypof\u00fdze. To stimuluje t\u011blo k uvol\u0148ov\u00e1n\u00ed vlastn\u00edho r\u016fstov\u00e9ho hormonu v p\u0159irozen\u00fdch pulzech, co\u017e n\u00e1sledn\u011b zvy\u0161uje hladinu inzul\u00ednu podobn\u00e9ho r\u016fstov\u00e9ho faktoru-1 (IGF-1). IGF-1 je hormon souvisej\u00edc\u00ed s metabolismem, regenerac\u00ed tk\u00e1n\u00ed, udr\u017een\u00edm svalov\u00e9 hmoty a bun\u011b\u010dn\u00fdm r\u016fstem. Na rozd\u00edl od p\u0159\u00edm\u00fdch injekc\u00ed r\u016fstov\u00e9ho hormonu, tesamorelin nenahrazuje GH z vn\u011bj\u0161ku. M\u00edsto toho stimuluje p\u0159irozen\u00fd syst\u00e9m r\u016fstov\u00e9ho hormonu t\u011bla.<\/p>\n<p data-start=\"1281\" data-end=\"2153\">V\u011bt\u0161ina studi\u00ed zam\u011b\u0159en\u00fdch na tesamorelin se soust\u0159edila na osoby \u017eij\u00edc\u00ed s HIV, u nich\u017e doch\u00e1z\u00ed b\u011bhem antiretrovir\u00e1ln\u00ed terapie k nadm\u011brn\u00e9mu hromad\u011bn\u00ed b\u0159i\u0161n\u00edho tuku. Klinick\u00e9 studie opakovan\u011b prok\u00e1zaly, \u017ee tesamorelin m\u016f\u017ee v\u00fdznamn\u011b sn\u00ed\u017eit mno\u017estv\u00ed viscer\u00e1ln\u00edho tuku, obvod pasu a tuk v oblasti trupu, p\u0159i\u010dem\u017e obvykle zachov\u00e1v\u00e1 podko\u017en\u00ed tuk, tedy tuk nach\u00e1zej\u00edc\u00ed se pod k\u016f\u017e\u00ed, a tak\u00e9 tuk v pa\u017e\u00edch a nohou. V placebem kontrolovan\u00fdch studi\u00edch trvaj\u00edc\u00edch 6 a\u017e 12 m\u011bs\u00edc\u016f byla \u010dasto pozorov\u00e1na redukce viscer\u00e1ln\u00edho tuku o p\u0159ibli\u017en\u011b 10\u201318%. V\u011bdci tak\u00e9 zaznamenali zlep\u0161en\u00ed vn\u00edm\u00e1n\u00ed vlastn\u00edho vzhledu a n\u011bkter\u00fdch ukazatel\u016f metabolick\u00e9ho zdrav\u00ed. Studie z\u00e1rove\u0148 uk\u00e1zaly, \u017ee po vysazen\u00ed tesamorelinu se viscer\u00e1ln\u00ed tuk postupn\u011b vracel, co\u017e nazna\u010duje, \u017ee udr\u017een\u00ed \u00fa\u010dink\u016f m\u016f\u017ee vy\u017eadovat pokra\u010dov\u00e1n\u00ed v l\u00e9\u010db\u011b.<\/p>\n<p data-start=\"2155\" data-end=\"2793\">Tesamorelin byl tak\u00e9 zkoum\u00e1n pro sv\u016fj vliv na ztu\u010dn\u011bn\u00ed jater a metabolick\u00e9 zdrav\u00ed. U jedinc\u016f s NAFLD souvisej\u00edc\u00edm s HIV studie uk\u00e1zaly sn\u00ed\u017een\u00ed mno\u017estv\u00ed tuku ukl\u00e1dan\u00e9ho v j\u00e1trech spolu se zlep\u0161en\u00edm metabolick\u00fdch marker\u016f souvisej\u00edc\u00edch s funkc\u00ed tohoto org\u00e1nu. D\u016fle\u017eit\u00e9 je, \u017ee tyto \u00fa\u010dinky byly pozorov\u00e1ny bez v\u00fdznamn\u00e9ho zhor\u0161en\u00ed kontroly hladiny cukru v krvi. V\u011bdci tak\u00e9 analyzovali potenci\u00e1ln\u00ed vliv tesamorelinu na z\u00e1n\u011bt, metabolismus tuk\u016f, kvalitu tukov\u00e9 tk\u00e1n\u011b, zdrav\u00e9 st\u00e1rnut\u00ed a mozkov\u00e9 funkce vzhledem k jeho p\u016fsoben\u00ed na dr\u00e1hy r\u016fstov\u00e9ho hormonu a IGF-1 souvisej\u00edc\u00ed s regenerac\u00ed a metabolismem.<\/p>\n<p data-start=\"2795\" data-end=\"3258\">Tesamorelin je pova\u017eov\u00e1n za peptid, proto\u017ee se skl\u00e1d\u00e1 z aminokyselin uspo\u0159\u00e1dan\u00fdch zp\u016fsobem napodobuj\u00edc\u00edm p\u0159irozen\u00fd lidsk\u00fd GHRH. Jedn\u00e1 se o modifikovanou a stabiln\u011bj\u0161\u00ed verzi p\u0159irozen\u00e9ho GHRH, navr\u017eenou tak, aby byla odoln\u011bj\u0161\u00ed v\u016f\u010di rozkladu enzymy v t\u011ble. D\u00edky tomu tesamorelin z\u016fst\u00e1v\u00e1 d\u00e9le aktivn\u00ed a \u00fa\u010dinn\u011bji stimuluje uvol\u0148ov\u00e1n\u00ed r\u016fstov\u00e9ho hormonu ne\u017e p\u0159irozen\u00fd GHRH, p\u0159i\u010dem\u017e si zachov\u00e1v\u00e1 p\u0159irozen\u011bj\u0161\u00ed vzorec vylu\u010dov\u00e1n\u00ed hormon\u016f.<\/p>\n<p data-start=\"3260\" data-end=\"3786\">V\u00fdzkumy rovn\u011b\u017e nazna\u010duj\u00ed, \u017ee tesamorelin m\u016f\u017ee zlep\u0161it slo\u017een\u00ed t\u011bla sn\u00ed\u017een\u00edm mno\u017estv\u00ed viscer\u00e1ln\u00edho tuku p\u0159i sou\u010dasn\u00e9m zv\u00fd\u0161en\u00ed beztukov\u00e9 t\u011blesn\u00e9 hmoty. N\u011bkolik klinick\u00fdch studi\u00ed a v\u011bdeck\u00fdch p\u0159ehled\u016f prok\u00e1zalo redukci obvodu pasu, mno\u017estv\u00ed tuku v trupu a jatern\u00edho tuku spolu se zv\u00fd\u0161en\u00edm svalov\u00e9 hmoty a hladin IGF-1. T\u011bchto zm\u011bn bylo obvykle dosa\u017eeno bez t\u011b\u017ek\u00fdch vedlej\u0161\u00edch \u00fa\u010dink\u016f nebo z\u00e1va\u017en\u00fdch hormon\u00e1ln\u00edch nerovnov\u00e1h, co\u017e odli\u0161uje tesamorelin od p\u0159\u00edm\u00e9 terapie r\u016fstov\u00fdm hormonem.<\/p>\n<p data-start=\"3788\" data-end=\"4238\">A\u010dkoli je tesamorelin prim\u00e1rn\u011b spojov\u00e1n s lipodystrofi\u00ed souvisej\u00edc\u00ed s HIV, v\u011bdeck\u00fd z\u00e1jem se roz\u0161\u00ed\u0159il i na dal\u0161\u00ed oblasti, jako jsou metabolick\u00e9 poruchy spojen\u00e9 s obezitou, ztu\u010dn\u011bn\u00ed jater, zdrav\u00e9 st\u00e1rnut\u00ed, kognitivn\u00ed funkce a biologie tukov\u00e9 tk\u00e1n\u011b. V\u011bdce zvl\u00e1\u0161t\u011b zaj\u00edm\u00e1 vliv analog\u016f GHRH na viscer\u00e1ln\u00ed tuk, mitochondri\u00e1ln\u00ed funkce, z\u00e1n\u011bt, metabolismus a mechanismy regenerace tk\u00e1n\u00ed.<\/p>\n<h3 data-section-id=\"12vzxnw\" data-start=\"4240\" data-end=\"4256\">Zastrze\u017cenie<\/h3>\n<p data-start=\"4258\" data-end=\"4818\">Informace t\u00fdkaj\u00edc\u00ed se tesamorelinu maj\u00ed v\u00fdhradn\u011b vzd\u011bl\u00e1vac\u00ed a v\u011bdeck\u00fd charakter. Tesamorelin je peptid na p\u0159edpis schv\u00e1len\u00fd pro specifick\u00e1 l\u00e9ka\u0159sk\u00e1 pou\u017eit\u00ed a v\u00fdzkum jeho \u0161ir\u0161\u00edch \u00fa\u010dink\u016f st\u00e1le prob\u00edh\u00e1. Zde popsan\u00e9 studie, mechanismy a v\u00fdsledky vych\u00e1zej\u00ed z publikovan\u00fdch v\u011bdeck\u00fdch \u00fadaj\u016f a nem\u011bly by b\u00fdt pova\u017eov\u00e1ny za l\u00e9ka\u0159skou radu, diagn\u00f3zu ani doporu\u010den\u00ed l\u00e9\u010dby. Jedinci zva\u017euj\u00edc\u00ed hormon\u00e1ln\u00ed terapie nebo intervence zalo\u017een\u00e9 na peptidech by se m\u011bli poradit s kvalifikovan\u00fdm zdravotnick\u00fdm pracovn\u00edkem.<\/p>\n<h2 data-section-id=\"xwtf3n\" data-start=\"4820\" data-end=\"4872\">Tesamorelin je syntetick\u00fd analog hormonu uvol\u0148uj\u00edc\u00edho r\u016fstov\u00fd hormon (GHRH), kter\u00fd je produkov\u00e1n v hypotalamu. Funguje tak, \u017ee se v\u00e1\u017ee na receptory GHRH v p\u0159edn\u00ed \u010d\u00e1sti hypof\u00fdzy. Tato vazba stimuluje hypof\u00fdzu k uvol\u0148ov\u00e1n\u00ed r\u016fstov\u00e9ho hormonu (GH), co\u017e je hormon, kter\u00fd hraje kl\u00ed\u010dovou roli v r\u016fstu, metabolismu a regeneraci bun\u011bk.\n\nKonkr\u00e9tn\u011b Tesamorelin pom\u00e1h\u00e1 stimulovat sekreci GH u pacient\u016f s lipodystrofi\u00ed spojenou s HIV. U t\u011bchto pacient\u016f doch\u00e1z\u00ed k abnorm\u00e1ln\u00edmu hromad\u011bn\u00ed tuku v ur\u010dit\u00fdch \u010d\u00e1stech t\u011bla a nedostatku tuku v jin\u00fdch \u010d\u00e1stech. Tesamorelin d\u00edky zv\u00fd\u0161en\u00ed hladiny GH podporuje sni\u017eov\u00e1n\u00ed viscer\u00e1ln\u00edho tuku (tuku v oblasti b\u0159icha), co\u017e je spojeno s r\u016fzn\u00fdmi zdravotn\u00edmi riziky.\n\nShrnut\u00ed mechanismu \u00fa\u010dinku Tesamorelinu:\n1.  **Vazba na GHRH receptory:** Tesamorelin se v\u00e1\u017ee na specifick\u00e9 receptory v hypof\u00fdze.\n2.  **Stimulace sekrece GH:** Tato vazba stimuluje hypof\u00fdzu k produkci a uvol\u0148ov\u00e1n\u00ed r\u016fstov\u00e9ho hormonu.\n3.  **Sn\u00ed\u017een\u00ed viscer\u00e1ln\u00edho tuku:** Zv\u00fd\u0161en\u00e1 hladina GH pak vede k lipol\u00fdze (rozkladu tuku), zejm\u00e9na v oblasti b\u0159icha.<\/h2>\n<p data-start=\"4874\" data-end=\"5473\">Tesamorelin p\u016fsob\u00ed tak, \u017ee napodobuje \u00fa\u010dinky p\u0159irozen\u00e9ho hormonu uvol\u0148uj\u00edc\u00edho r\u016fstov\u00fd hormon (GHRH), kter\u00fd je zodpov\u011bdn\u00fd za p\u0159enos sign\u00e1lu do hypof\u00fdzy, aby uvolnila r\u016fstov\u00fd hormon (GH). Po pod\u00e1n\u00ed se tesamorelin v\u00e1\u017ee na receptory GHRH na bu\u0148k\u00e1ch hypof\u00fdzy zvan\u00fdch somatotropn\u00ed bu\u0148ky. To vede k uvol\u0148ov\u00e1n\u00ed p\u0159irozen\u00e9ho r\u016fstov\u00e9ho hormonu t\u011bla v p\u0159irozen\u00fdch pulzech. Jak hladina GH stoup\u00e1, j\u00e1tra za\u010dnou produkovat v\u00edce inzul\u00ednu podobn\u00e9ho r\u016fstov\u00e9ho faktoru-1 (IGF-1), kter\u00fd je zodpov\u011bdn\u00fd za mnoho metabolick\u00fdch \u00fa\u010dink\u016f a zm\u011bn t\u011blesn\u00e9ho slo\u017een\u00ed spojen\u00fdch s tesamorelinem.<\/p>\n<p data-start=\"5475\" data-end=\"5944\">Nejd\u016fle\u017eit\u011bj\u0161\u00ed vlastnost\u00ed mechanismu \u00fa\u010dinku tesamorelinu je, \u017ee posiluje p\u0159irozen\u00fd syst\u00e9m r\u016fstov\u00e9ho hormonu v t\u011ble nam\u00edsto p\u0159\u00edm\u00e9ho nahrazov\u00e1n\u00ed r\u016fstov\u00e9ho hormonu. To je d\u016fle\u017eit\u00e9, proto\u017ee to umo\u017e\u0148uje zachovat p\u0159irozen\u00fd hormon\u00e1ln\u00ed zp\u011btnovazebn\u00fd mechanismus. Na rozd\u00edl od p\u0159\u00edm\u00fdch injekc\u00ed GH si tesamorelin udr\u017euje pulzativn\u00ed sekreci r\u016fstov\u00e9ho hormonu, co\u017e znamen\u00e1, \u017ee GH je uvol\u0148ov\u00e1n v rytmick\u00fdch d\u00e1vk\u00e1ch p\u0159ipom\u00ednaj\u00edc\u00edch p\u0159irozenou fyziologii.<\/p>\n<p data-start=\"5946\" data-end=\"6669\">Na poziomie metabolicznym tesamorelin pom\u00e1h\u00e1 rozkl\u00e1dat ulo\u017een\u00fd tuk, zejm\u00e9na viscer\u00e1ln\u00ed tuk nach\u00e1zej\u00edc\u00ed se hluboko v b\u0159i\u0161n\u00ed dutin\u011b. R\u016fstov\u00fd hormon aktivuje enzymy zapojen\u00e9 do lipol\u00fdzy, tedy procesu rozkladu triglycerid\u016f nahromad\u011bn\u00fdch v tukov\u00fdch bu\u0148k\u00e1ch. Viscer\u00e1ln\u00ed tuk je obzvl\u00e1\u0161t\u011b citliv\u00fd na r\u016fstov\u00fd hormon, proto\u017ee obsahuje mnoho receptor\u016f reaguj\u00edc\u00edch na GH a vyzna\u010duje se vysokou metabolickou aktivitou. Z tohoto d\u016fvodu tesamorelin p\u016fsob\u00ed p\u0159ev\u00e1\u017en\u011b na hlubok\u00fd b\u0159i\u0161n\u00ed tuk, p\u0159i\u010dem\u017e \u010dasto zachov\u00e1v\u00e1 podko\u017en\u00ed tuk. Klinick\u00e9 studie konzistentn\u011b prok\u00e1zaly sn\u00ed\u017een\u00ed mno\u017estv\u00ed viscer\u00e1ln\u00edho tuku, obvodu pasu a tuku v oblasti trupu b\u011bhem terapie tesamorelinem.<\/p>\n<p data-start=\"6671\" data-end=\"7304\">Dal\u0161\u00ed d\u016fle\u017eitou sou\u010d\u00e1st\u00ed \u00fa\u010dinku tesamorelinu je zv\u00fd\u0161en\u00ed hladiny IGF-1. Tento hormon je produkov\u00e1n p\u0159ev\u00e1\u017en\u011b v j\u00e1trech po stimulaci r\u016fstov\u00fdm hormonem a podporuje udr\u017een\u00ed svalov\u00e9 hmoty, regeneraci tk\u00e1n\u00ed, synt\u00e9zu b\u00edlkovin a metabolismus. Vy\u0161\u0161\u00ed hladiny IGF-1 jsou spojeny se zv\u00fd\u0161en\u00edm beztukov\u00e9 t\u011blesn\u00e9 hmoty, lep\u0161\u00edmi regenera\u010dn\u00edmi procesy a zlep\u0161enou bun\u011b\u010dnou opravou. N\u011bkter\u00e9 studie tak\u00e9 nazna\u010duj\u00ed, \u017ee IGF-1 m\u016f\u017ee podporovat zdrav\u00ed mozku, mitochondri\u00e1ln\u00ed funkce, protiz\u00e1n\u011btlivou signalizaci a ochranu nervov\u00fdch bun\u011bk, proto tesamorelin vzbudil z\u00e1jem ve v\u00fdzkumu st\u00e1rnut\u00ed a kognitivn\u00edch funkc\u00ed.<\/p>\n<p data-start=\"7306\" data-end=\"7781\">Tesamorelin m\u016f\u017ee tak\u00e9 zlep\u0161it zdrav\u00ed jater a metabolismus tuk\u016f. Ve studi\u00edch o ztu\u010dn\u011bn\u00ed jater spojen\u00e9m s HIV tesamorelin sn\u00ed\u017eil mno\u017estv\u00ed tuku hromad\u00edc\u00edho se v j\u00e1trech. V\u011bdci se domn\u00edvaj\u00ed, \u017ee to m\u016f\u017ee b\u00fdt zp\u016fsobeno n\u011bkolika mechanismy, v\u010detn\u011b zv\u00fd\u0161en\u00e9ho spalov\u00e1n\u00ed tuk\u016f, sn\u00ed\u017een\u00e9 produkce nov\u00fdch tuk\u016f v j\u00e1trech, lep\u0161\u00edho rozlo\u017een\u00ed tuk\u016f v t\u011ble a omezen\u00ed transportu mastn\u00fdch kyselin z viscer\u00e1ln\u00edho tuku do jater.<\/p>\n<p data-start=\"7783\" data-end=\"8257\">Dal\u0161\u00ed d\u016fle\u017eit\u00fd \u00fa\u010dinek se t\u00fdk\u00e1 z\u00e1n\u011btu a kvality tukov\u00e9 tk\u00e1n\u011b. Nadm\u011brn\u00fd viscer\u00e1ln\u00ed tuk je siln\u011b spojen s chronick\u00fdm z\u00e1n\u011btem n\u00edzk\u00e9ho stupn\u011b, inzulinovou rezistenc\u00ed a metabolick\u00fdmi poruchami. Sn\u00ed\u017een\u00edm mno\u017estv\u00ed viscer\u00e1ln\u00edho tuku m\u016f\u017ee tesamorelin nep\u0159\u00edmo zlep\u0161ovat z\u00e1n\u011btliv\u00e9 a metabolick\u00e9 markery. V n\u011bkter\u00fdch studi\u00edch byla b\u011bhem terapie pozorov\u00e1na zlep\u0161en\u00ed hladiny triglycerid\u016f, adiponektinu a dal\u0161\u00edch metabolick\u00fdch ukazatel\u016f.<\/p>\n<p data-start=\"8259\" data-end=\"8968\">Tesamorelin byl tak\u00e9 zkoum\u00e1n pro sv\u016fj mo\u017en\u00fd vliv na mozkov\u00e9 funkce, proto\u017ee r\u016fstov\u00fd hormon a IGF-1 ovliv\u0148uj\u00ed mnoho neurologick\u00fdch proces\u016f. IGF-1 m\u016f\u017ee proch\u00e1zet hematoencefalickou bari\u00e9rou a pod\u00edl\u00ed se na tvorb\u011b nov\u00fdch neuron\u016f, udr\u017eov\u00e1n\u00ed \u017eivota nervov\u00fdch bun\u011bk, zlep\u0161ov\u00e1n\u00ed komunikace mezi neurony a omezov\u00e1n\u00ed oxida\u010dn\u00edho stresu. V\u011bdci analyzovali, zda sn\u00ed\u017een\u00ed b\u0159i\u0161n\u00edho tuku a zv\u00fd\u0161en\u00ed IGF-1 m\u016f\u017ee zlep\u0161it kognitivn\u00ed funkce u lid\u00ed s HIV spojen\u00fdmi neurokognitivn\u00edmi poruchami. A\u010dkoli n\u011bkter\u00e9 studie prok\u00e1zaly zv\u00fd\u0161en\u00ed hladiny IGF-1 a sn\u00ed\u017een\u00ed obvodu pasu, zlep\u0161en\u00ed kognitivn\u00edch funkc\u00ed bylo obvykle m\u00edrn\u00e9 a ne v\u017edy statisticky v\u00fdznamn\u00e9.<\/p>\n<p data-start=\"8970\" data-end=\"9358\">Z hlediska farmaceutick\u00e9ho designu byl tesamorelin vytvo\u0159en jako stabilizovan\u00e1 verze GHRH. P\u0159irozen\u00fd GHRH se v t\u011ble velmi rychle rozkl\u00e1d\u00e1, co\u017e omezuje jeho pou\u017eit\u00ed. Tesamorelin obsahuje struktur\u00e1ln\u00ed zm\u011bny, kter\u00e9 zvy\u0161uj\u00ed jeho odolnost v\u016f\u010di enzymatick\u00e9mu rozkladu, a proto z\u016fst\u00e1v\u00e1 aktivn\u00ed d\u00e9le a po subkut\u00e1nn\u00edm pod\u00e1n\u00ed \u00fa\u010dinn\u011bji stimuluje uvol\u0148ov\u00e1n\u00ed r\u016fstov\u00e9ho hormonu.<\/p>\n<p data-start=\"9360\" data-end=\"9918\">Obecn\u011b \u0159e\u010deno, tesamorelin funguje jako c\u00edlen\u00fd peptid posiluj\u00edc\u00ed p\u0159irozen\u00fd syst\u00e9m r\u016fstov\u00e9ho hormonu t\u011bla. Jeho \u00fa\u010dinky zahrnuj\u00ed signalizaci r\u016fstov\u00e9ho hormonu, produkci IGF-1, metabolismus viscer\u00e1ln\u00edho tuku, regulaci jatern\u00edho tuku a dr\u00e1hy regenerace tk\u00e1n\u00ed. Tato kombinace \u00fa\u010dink\u016f vysv\u011btluje, pro\u010d byl tesamorelin rozs\u00e1hle studov\u00e1n v souvislosti se sn\u00ed\u017een\u00edm viscer\u00e1ln\u00edho tuku, HIV-asociovanou lipodystrofi\u00ed, ztu\u010dn\u011bn\u00edm jater, metabolick\u00fdmi poruchami a dal\u0161\u00edmi probl\u00e9my souvisej\u00edc\u00edmi s nespr\u00e1vn\u00fdm rozlo\u017een\u00edm t\u011blesn\u00e9ho tuku.<\/p>\n<h3 data-section-id=\"12vzxnw\" data-start=\"9920\" data-end=\"9936\">Zastrze\u017cenie<\/h3>\n<p data-start=\"9938\" data-end=\"10389\" data-is-last-node=\"\" data-is-only-node=\"\">Toto vysv\u011btlen\u00ed mechanismu \u00fa\u010dinku tesamorelinu m\u00e1 v\u00fdhradn\u011b eduka\u010dn\u00ed a v\u011bdeck\u00fd charakter. A\u010dkoli klinick\u00e9 a preklinick\u00e9 studie analyzovaly \u00fa\u010dinky tesamorelinu na signalizaci r\u016fstov\u00e9ho hormonu, metabolismus, zdrav\u00ed jater a slo\u017een\u00ed t\u011bla, studie jeho dlouhodob\u00e9 bezpe\u010dnosti a \u0161ir\u0161\u00edch \u00fa\u010dink\u016f st\u00e1le prob\u00edhaj\u00ed. Obsah neslou\u017e\u00ed jako l\u00e9ka\u0159sk\u00e1 rada a nenahrazuje konzultaci s licencovan\u00fdm zdravotn\u00edkem.<\/p>\n<h4>Odkazy<\/h4>\n<ul>\n<li data-start=\"368\" data-end=\"839\"><span style=\"font-size: 10pt;\">Falutz, J., Potvin, D., Mamputu, J.-C., Assaad, H., Zoltowska, M., Michaud, S.-E., Berger, D., Somero, M., Moyle, G., Brown, S., Martorell, C., Turner, R., &amp; Grinspoon, S. (2010). \u00da\u010dinky tesamorelinu, faktoru uvol\u0148uj\u00edc\u00edho r\u016fstov\u00fd hormon, u pacient\u016f s HIV a hromad\u011bn\u00edm b\u0159i\u0161n\u00edho tuku: Randomizovan\u00e1 placebem kontrolovan\u00e1 studie s prodlou\u017een\u00edm bezpe\u010dnosti. <em data-start=\"728\" data-end=\"781\">Journal of Acquired Immune Deficiency Syndromes, 53<\/em>(3), 311\u2013322. <a class=\"decorated-link cursor-pointer\" target=\"_new\" rel=\"noopener\" data-start=\"795\" data-end=\"839\">https:\/\/doi.org\/10.1097\/QAI.0b013e3181cbdaff<\/a><\/span><\/li>\n<li data-start=\"841\" data-end=\"1144\"><span style=\"font-size: 10pt;\">Ellis, R. J., Vaida, F., Hu, K., Dube, M., Henry, B., Chow, F., Heaton, R. K., Lee, D., &amp; Sattler, F. S. (2025). \u00da\u010dinky tesamorelina na neurokognitivn\u00ed posti\u017een\u00ed u osob s HIV a b\u0159i\u0161n\u00ed obezitou. <em data-start=\"1049\" data-end=\"1090\">The Journal of Infectious Diseases, 231<\/em>(5), 1230\u20131238. <a class=\"decorated-link\" href=\"https:\/\/doi.org\/10.1093\/infdis\/jiaf012\" target=\"_new\" rel=\"noopener\" data-start=\"1106\" data-end=\"1144\">https:\/\/doi.org\/10.1093\/infdis\/jiaf012<\/a><\/span><\/li>\n<li data-start=\"1146\" data-end=\"1442\"><span style=\"font-size: 10pt;\">Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S. a kol. (2019). \u00da\u010dinky tesamorelinu na nealkoholick\u00e9 steat\u00f3zn\u00ed onemocn\u011bn\u00ed jater u HIV: Randomizovan\u00e1, dvojit\u011b zaslepen\u00e1, multicentrick\u00e1 studie. <em data-start=\"1361\" data-end=\"1380\">The Lancet HIV, 6<\/em>(12), e821\u2013e830. <a class=\"decorated-link cursor-pointer\" target=\"_new\" rel=\"noopener\" data-start=\"1397\" data-end=\"1442\">https:\/\/doi.org\/10.1016\/S2352-3018(19)30338-8<\/a><\/span><\/li>\n<li data-start=\"1444\" data-end=\"1791\"><span style=\"font-size: 10pt;\">Rahman, F., McLaughlin, T., Mesquita, P., Morin, J., Potvin, D., De Chantal, M., &amp; Aberg, J. A. (2022). \u00da\u010dinek tesamorelina u lid\u00ed s HIV s dorsocervik\u00e1ln\u00edm tukem i bez n\u011bj: Posthocov\u00e1 anal\u00fdza f\u00e1ze III dvojit\u011b zaslepen\u00e9 placebem kontrolovan\u00e9 studie. <em data-start=\"1695\" data-end=\"1745\">Journal of Clinical and Translational Science, 7<\/em>(1), e40. <a class=\"decorated-link cursor-pointer\" target=\"_new\" rel=\"noopener\" data-start=\"1755\" data-end=\"1791\">https:\/\/doi.org\/10.1017\/cts.2022.515<\/a><\/span><\/li>\n<li data-start=\"1793\" data-end=\"2125\"><span style=\"font-size: 10pt;\">Badran, A. S., Helal, A., Shata, K. S., &amp; Ayesh, H. (2026). Slo\u017een\u00ed t\u011bla, jatern\u00ed tuk, metabolick\u00e9 a bezpe\u010dnostn\u00ed v\u00fdsledky tesamorelinu, analogu GHRH, u lipodystrofie spojen\u00e9 s HIV: Metaanal\u00fdza randomizovan\u00fdch kontrolovan\u00fdch studi\u00ed. <em data-start=\"2030\" data-end=\"2072\">Obesity Research &amp; Clinical Practice, 20<\/em>(1), 2\u201312. <a class=\"decorated-link cursor-pointer\" target=\"_new\" rel=\"noopener\" data-start=\"2083\" data-end=\"2125\">https:\/\/doi.org\/10.1016\/j.orcp.2026.01.002<\/a><\/span><\/li>\n<li data-start=\"2254\" data-end=\"2725\"><span style=\"font-size: 10pt;\">Falutz, J., Potvin, D., Mamputu, J.-C., Assaad, H., Zoltowska, M., Michaud, S.-E., Berger, D., Somero, M., Moyle, G., Brown, S., Martorell, C., Turner, R., &amp; Grinspoon, S. (2010). \u00da\u010dinky tesamorelinu, faktoru uvol\u0148uj\u00edc\u00edho r\u016fstov\u00fd hormon, u pacient\u016f s HIV a hromad\u011bn\u00edm b\u0159i\u0161n\u00edho tuku: Randomizovan\u00e1 placebem kontrolovan\u00e1 studie s prodlou\u017een\u00edm bezpe\u010dnosti. <em data-start=\"2614\" data-end=\"2667\">Journal of Acquired Immune Deficiency Syndromes, 53<\/em>(3), 311\u2013322. <a class=\"decorated-link cursor-pointer\" target=\"_new\" rel=\"noopener\" data-start=\"2681\" data-end=\"2725\">https:\/\/doi.org\/10.1097\/QAI.0b013e3181cbdaff<\/a><\/span><\/li>\n<li data-start=\"2727\" data-end=\"3030\"><span style=\"font-size: 10pt;\">Ellis, R. J., Vaida, F., Hu, K., Dube, M., Henry, B., Chow, F., Heaton, R. K., Lee, D., &amp; Sattler, F. S. (2025). \u00da\u010dinky tesamorelina na neurokognitivn\u00ed posti\u017een\u00ed u osob s HIV a b\u0159i\u0161n\u00ed obezitou. <em data-start=\"2935\" data-end=\"2976\">The Journal of Infectious Diseases, 231<\/em>(5), 1230\u20131238. <a class=\"decorated-link\" href=\"https:\/\/doi.org\/10.1093\/infdis\/jiaf012\" target=\"_new\" rel=\"noopener\" data-start=\"2992\" data-end=\"3030\">https:\/\/doi.org\/10.1093\/infdis\/jiaf012<\/a><\/span><\/li>\n<li data-start=\"3032\" data-end=\"3328\"><span style=\"font-size: 10pt;\">Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S. a kol. (2019). \u00da\u010dinky tesamorelinu na nealkoholick\u00e9 steat\u00f3zn\u00ed onemocn\u011bn\u00ed jater u HIV: Randomizovan\u00e1, dvojit\u011b zaslepen\u00e1, multicentrick\u00e1 studie. <em data-start=\"3247\" data-end=\"3266\">The Lancet HIV, 6<\/em>(12), e821\u2013e830. <a class=\"decorated-link cursor-pointer\" target=\"_new\" rel=\"noopener\" data-start=\"3283\" data-end=\"3328\">https:\/\/doi.org\/10.1016\/S2352-3018(19)30338-8<\/a><\/span><\/li>\n<li data-start=\"3330\" data-end=\"3677\"><span style=\"font-size: 10pt;\">Rahman, F., McLaughlin, T., Mesquita, P., Morin, J., Potvin, D., De Chantal, M., &amp; Aberg, J. A. (2022). \u00da\u010dinek tesamorelina u lid\u00ed s HIV s dorsocervik\u00e1ln\u00edm tukem i bez n\u011bj: Posthocov\u00e1 anal\u00fdza f\u00e1ze III dvojit\u011b zaslepen\u00e9 placebem kontrolovan\u00e9 studie. <em data-start=\"3581\" data-end=\"3631\">Journal of Clinical and Translational Science, 7<\/em>(1), e40. <a class=\"decorated-link cursor-pointer\" target=\"_new\" rel=\"noopener\" data-start=\"3641\" data-end=\"3677\">https:\/\/doi.org\/10.1017\/cts.2022.515<\/a><\/span><\/li>\n<li data-start=\"3679\" data-end=\"4011\"><span style=\"font-size: 10pt;\">Badran, A. S., Helal, A., Shata, K. S., &amp; Ayesh, H. (2026). Slo\u017een\u00ed t\u011bla, jatern\u00ed tuk, metabolick\u00e9 a bezpe\u010dnostn\u00ed v\u00fdsledky tesamorelinu, analogu GHRH, u lipodystrofie spojen\u00e9 s HIV: Metaanal\u00fdza randomizovan\u00fdch kontrolovan\u00fdch studi\u00ed. <em data-start=\"3916\" data-end=\"3958\">Obesity Research &amp; Clinical Practice, 20<\/em>(1), 2\u201312. <a class=\"decorated-link cursor-pointer\" target=\"_new\" rel=\"noopener\" data-start=\"3969\" data-end=\"4011\" data-is-last-node=\"\">https:\/\/doi.org\/10.1016\/j.orcp.2026.01.002<\/a><\/span><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>Tesamorelin je syntetick\u00fd peptid, kter\u00fd pom\u00e1h\u00e1 t\u011blu p\u0159irozen\u011b zvy\u0161ovat produkci a uvol\u0148ov\u00e1n\u00ed r\u016fstov\u00e9ho hormonu (GH). Byl navr\u017een tak, aby napodoboval \u00fa\u010dinek hormonu uvol\u0148uj\u00edc\u00edho r\u016fstov\u00fd hormon (GHRH),\u2026<\/p>","protected":false},"author":7908,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[236],"tags":[],"class_list":["post-47928","post","type-post","status-publish","format-standard","hentry","category-kategoria-tesamorelin","beh-no-thumb"],"_links":{"self":[{"href":"https:\/\/bioevidencehub.com\/cs\/wp-json\/wp\/v2\/posts\/47928","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bioevidencehub.com\/cs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bioevidencehub.com\/cs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bioevidencehub.com\/cs\/wp-json\/wp\/v2\/users\/7908"}],"replies":[{"embeddable":true,"href":"https:\/\/bioevidencehub.com\/cs\/wp-json\/wp\/v2\/comments?post=47928"}],"version-history":[{"count":0,"href":"https:\/\/bioevidencehub.com\/cs\/wp-json\/wp\/v2\/posts\/47928\/revisions"}],"wp:attachment":[{"href":"https:\/\/bioevidencehub.com\/cs\/wp-json\/wp\/v2\/media?parent=47928"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bioevidencehub.com\/cs\/wp-json\/wp\/v2\/categories?post=47928"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bioevidencehub.com\/cs\/wp-json\/wp\/v2\/tags?post=47928"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}